Guideline for the treatment of Hansen's disease in Japan.
-
- Goto Masamichi
- Department of Pathology, Faculty of Medicine, Kagoshima University ad hoc committee on treatment guideline and judgement of cure, Japanese Leprosy Association
-
- Ishida Yutaka
- International Medical Cooperation Bureau, International Medical Center ad hoc committee on treatment guideline and judgement of cure, Japanese Leprosy Association
-
- Gidoh Masaichi
- National Institute for Infectious Disease, Leprosy Research Center ad hoc committee on treatment guideline and judgement of cure, Japanese Leprosy Association
-
- Nagao Eiji
- National Hansen's Disease Sanatorium, Ohshima-Seishoen ad hoc committee on treatment guideline and judgement of cure, Japanese Leprosy Association
-
- Namisato Masako
- National Hansen's Disease Sanatorium, Tama-Zenshoen ad hoc committee on treatment guideline and judgement of cure, Japanese Leprosy Association
-
- Ishii Norihisa
- National Institute for Infectious Disease, Leprosy Research Center ad hoc committee on treatment guideline and judgement of cure, Japanese Leprosy Association
-
- Ozaki Motoaki
- Hyogo Prefectural Amagasaki Hospital ad hoc committee on treatment guideline and judgement of cure, Japanese Leprosy Association
Bibliographic Information
- Other Title
-
- ハンセン病治療指針
Search this article
Abstract
ad hoc committee of Japanese Leprosy Association recommends standard treatment protocol of leprosy in Japan, which is a modification of World Health Organization's multidrug therapy (WHO/MDT, 1997). For paucibacillary (PB) leprosy, 6 months treatment by rifampicin and dapsone (MDT/PB) is enough. However, for high bacterial load multibacillary (MB) leprosy, 12 months treatment seems insufficient. Thus, (A) For MB with bacterial index (BI) ≥3 before treatment, 2 years treatment by rifampicin, dapsone and clofazimine (MDT/MB) is necessary. (A-1) When satisfactory decrease of BI (BI value decrease≥2 steps, or final BI<3) is obtained after completion of 2 years MDT/MB, maintenance therapy by dapsone and clofazimine is recommended until BI negativity and loss of active lesions. (A-2) When BI decrease is not satisfactory (BI value decrease <2 steps, or final BI≥3), MDT/MB should be continued until BI negativity and loss of active lesions. (B) For MB with BI<3 or fresh MB (less than 6 months after the onset of the disease) with BI≥3, 1 year treatment by rifampicin, dapsone and clofazimine (MDT/MB) is necessary. (B-1) When BI become negative and active lesion is lost within one year, no maintenance therapy is necessary. (B-2) When BI is still positive or active lesion is remaining, additional therapy with MDT/MB for one more year is recommended. Brief summary of diagnosis, purpose of therapy, character of drugs, and prevention of deformity is also described.
Journal
-
- JAPANESE JOURNAL OF LEPROSY
-
JAPANESE JOURNAL OF LEPROSY 69 (3), 157-177, 2000
Japanese Leprosy Association
- Tweet
Details
-
- CRID
- 1390001206322439808
-
- NII Article ID
- 10009795284
-
- NII Book ID
- AN10559906
-
- COI
- 1:STN:280:DC%2BD3M7jslGqtQ%3D%3D
-
- ISSN
- 1884314X
- 13423681
-
- PubMed
- 11187723
-
- Text Lang
- ja
-
- Data Source
-
- JaLC
- Crossref
- PubMed
- CiNii Articles
-
- Abstract License Flag
- Disallowed